Scientists from the Florida campus of The Scripps Research Institute, the University of California, San Diego, and the University of Illinois have found that two immune system molecules (interleukin 1 beta and tumor necrosis factor alpha) may be key to the development of drug resistance in estrogen-driven breast cancers. The researchers believe this finding may open the door to novel therapeutic approaches and influence treatment decisions.
MedicalXpress